Episode Details
Back to Episodes
Lilly’s Alzheimer’s Push Ignites Stock | Business and Finance News
Description
Eli Lilly’s stock surged as it unveiled major drug deals, including a $10M upfront payment for Alzheimer’s preclinical asset ACD680 — potentially worth over $1B with milestones and royalties — plus a new ion channel program with OmniAb that could net hundreds of millions. These moves bolster their Alzheimer’s pipeline alongside existing blockbuster drugs like Kisunla, signaling strategic depth. Their recent earnings crushed forecasts: 50% YoY revenue growth fueled by obesity drugs Mounjaro and Zepbound, driving them to raise full-year guidance and push market cap toward $1T — all while investors see these bets as smart, not wild.
Listen in comfort:
Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn.
Advertise on DNN:
advertise@thednn.ai
This is an automated, high-level news summary based on public reporting.
Report issues to feedback@thednn.ai.
View sources & latest updates:
https://sources.thednn.ai/7bdebc3862cd2a44